Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer

Journal of Oncology Practice

Volumn 7, Issue 2, 2011, Pages 94-99

  Oratz, Ruth ^a,b,c,d,e   Kim, Benjamin ^a,b,c,d,e   Chao, Calvin ^a,b,c,d,e   Skrzypczak, Stanley ^a,b,c,d,e   Ory, Caron ^a,b,c,d,e   Bugarini, Roberto ^a,b,c,d,e   Broder, Michael ^a,b,c,d,e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RAND CORPORATION   (United States)

^d Genomic Health Inc   (United States)

^e PARTNERSHIP FOR HEALTH ANALYTIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; PROGESTERONE RECEPTOR;

21 GENE RECURRENCE SCORE; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; COMMUNITY HOSPITAL; COMORBIDITY; FEMALE; HEALTH SURVEY; HUMAN; LIFE EXPECTANCY; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; PHYSICIAN; PROGNOSIS; QUALITY OF LIFE; SCORING SYSTEM; TUMOR VOLUME; UNIVERSITY HOSPITAL;

EID: 79960168661     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2010.000046     Document Type: Article

References (28)

1. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004 (Pubitemid 40051905)
2. Mamounas EP, Tang G, Fisher B, et al: Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20. J Clin Oncol 28:1677-1683, 2010
3. Fisher B, Jeong JH, Bryant J, et al: Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364:858-868, 2004
4. Oratz R, Paul D, Cohn AL, et al: Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract 3:182-186, 2007 (Pubitemid 351593669)
5. Liang H, Brufsky AM, Lembersky BB, et al: A retrospective analysis of the impact of Oncotype DX low recurrence score results on treatment decisions in a single academic breast cancer center. Presented at the 30th annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007 (abstr 2061)
6. Mumby PB, Lo SS, Norton J, et al: Prospective multi-center study of the impact of the 21-gene recurrence score assay on patient satisfaction, anxiety and decisional conflict for adjuvant breast cancer treatment selection. Presented at the 30th annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007 (abstr 2092)
7. Erb C, Fox KR, Patel M, et al: Evaluation of practice patterns in the treatment of node-negative, hormone-receptor positive breast cancer patients with the use of the Oncotype DX assay at the University of Pennsylvania. Presented at the 30th annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007 (abstr 3082)
8. Ben-Baruch N, Hammerman A, Klang S, et al: A prospective study of the impact of the 21-gene recurrence score assay on treatment decisions in N-, ER+ early stage breast cancer patients. J Clin Oncol 25:18S, 2007 (suppl, abstr 11008)
9. National Comprehensive Cancer Network. The NCCN breast cancer clinical practice guidelines (v. 2.2008). http://www.nccn.org
10. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007
11. Goldstein LJ, Gray R, Badve S, et al: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 25:4063-4071, 2008
12. Albain KS, Barlow WE, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 11:55-65, 2010
13. Dowsett M, Cuzick J, Wale C, et al: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A transATAC study. J Clin Oncol 28:1829-1834, 2010
14. Rogers EM: Diffusion of Innovations (ed 4). New York, NY, Free Press, 1995, pp 280-282
15. Berwick DM: Disseminating innovations in health care. JAMA 289:1969-1975, 2003
16. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2005
17. Gianni L, Zambetti M, Clark K, et al: Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally-advanced breast cancer. J Clin Oncol 23:7265-7277, 2005 (Pubitemid 46202341)
18. Chang JC, Makris A, Gutierrez MC, et al: Gene expression profiles in formalin-fixed, paraffin-embedded core biopsy tissue predict docetaxel chemosensitivity. Breast Cancer Res Treat 108:233-240, 2008 (Pubitemid 351311356)
19. Akashi-Tanaka S, Shimizu C, Ando M, et al: 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. Breast 18:171-174, 2009
20. Paik S, Tang G, Fumagalli D: An ideal prognostic test for estrogen receptor-positive breast cancer? J Clin Oncol 25:4058-4059, 2008
21. Wolf I, Ben-Baruch N, Shapira-Frommer R, et al: Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients. Cancer 112:731-736, 2008 (Pubitemid 351240566)
22. Asad J, Jacobson AF, Estabrook A, et al: Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg: 196:527-529, 2008
23. Henry LR, Stojadinovic A, Swain SM, et al: The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 99:319-323, 2009
24. Hornberger J, Cosler LE, Lyman GH: Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 11:313-324, 2005 (Pubitemid 40646936)
25. Lyman GH, Cosler LE, Kuderer NM, et al: Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: An economic analysis based on prognostic and predictive validation studies. Cancer 109:1011-1018, 2007 (Pubitemid 46435378)
26. Lo SS, Mumby PB, Norton J, et al: Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28:1671-1676, 2010
27. Helft PR, Hlubocky F, Daugherty CK: American oncologists' views of Internet use by cancer patients: A mail survey of American Society of Clinical Oncology members. J Clin Oncol 21:942-947, 2003 (Pubitemid 46606457)
28. Fenton L, Rigney M, Herbst RS: Clinical trial awareness, attitudes, and participation among patients with cancer and oncologists. Commun Oncol 6:207-213, 2009